Abstract CT202: CSFctDNA as a surrogate for tumor tissue DNA in BC pts with CNS metastases: First results from the Brainstorm program (Oncodistinct 006)
Nuria Kotecki(Centre Oscar Lambret), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell), Caroline Duhem(Centre Hospitalier de Luxembourg), Anthony Gonçalvès(Centre National de la Recherche Scientifique), Jean-Luc Canon(Grand Charleroi Hospital), Hannelore Denys(Ghent University Hospital), Luca Arecco(Ospedale Policlinico San Martino), Claire Cheymol(Centre Oscar Lambret), Nadège Kindt(University of Mons), François P. Duhoux(Cliniques Universitaires Saint-Luc), Guilherme Nader Marta(Université Libre de Bruxelles), Lore Decoster(Universitair Ziekenhuis Brussel), Florian Clatot, Vincent Vanhaudenarde(CHU Dinant Godinne UCL Namur), Joseph Gligorov(Sorbonne Université), Stéphane Holbrechts(CHU Ambroise Paré), Édith Borcoman(Institut Curie), Eleonora Stephane de Maio D’Esposito(Institut Claudius Regaud), Philippe Barthélémy(Institut de Cancérologie Strasbourg), Andrea Gombos(Institut Jules Bordet), Paul M. Clément(Universitair Ziekenhuis Leuven), Florence Lefranc(Université Libre de Bruxelles), Diogo Martins-Branco(Université Libre de Bruxelles)
Cited by 1
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994